What is the appropriate acute and chronic verapamil regimen for a 45‑year‑old active patient with documented narrow‑complex supraventricular tachycardia (191 bpm) and a negative stress test, assuming no structural heart disease, heart failure, severe left‑ventricular dysfunction, hypotension, or AV‑node block?

Verapamil Dosing for Narrow-Complex SVT

For acute management of your documented narrow-complex SVT, start with intravenous verapamil 5–10 mg administered over 2–3 minutes (or up to 20 minutes to minimize hypotension risk), and for chronic suppression after successful conversion, initiate oral verapamil 120–180 mg daily with food, titrating upward to 240–320 mg daily based on recurrence. 1, 2, 3

Acute Management Regimen

Intravenous Verapamil Protocol

• Administer 5–10 mg IV verapamil over 2–3 minutes as third-line therapy after failed vagal maneuvers and adenosine. 1
• Alternatively, infuse verapamil at 1 mg/min (up to 20 mg total) to reduce hypotension risk; this approach achieved 100% success in controlling SVT without blood pressure depression in prospective studies. 1, 4
• IV verapamil converts 64–98% of narrow-complex SVT episodes, making it highly effective when adenosine fails or is contraindicated. 1
• Pretreatment with 1 g IV calcium salts before verapamil infusion prevents hypotension while maintaining efficacy (mean effective dose 20 mg). 4

Critical Safety Checks Before IV Verapamil

• Never administer verapamil if there is any possibility of wide-QRS tachycardia, pre-excited atrial fibrillation (Wolff-Parkinson-White), ventricular tachycardia, severe left ventricular dysfunction (ejection fraction <30%), systolic blood pressure <90 mmHg, or second/third-degree AV block. 1, 2
• Have a defibrillator immediately available, as with adenosine, because calcium-channel blockers can precipitate dangerous arrhythmias in misdiagnosed cases. 1
• Avoid verapamil in patients taking beta-blockers or other negative inotropes due to additive cardiodepressant effects. 2

Chronic Oral Maintenance Regimen

Initial Dosing

• Start oral verapamil 120–180 mg once daily in the morning with food (the FDA-approved starting dose for extended-release formulations). 2
• Lower initial doses of 120 mg daily are warranted in elderly patients or those with small body habitus who may have increased drug response. 2

Titration Strategy

• Assess therapeutic efficacy and safety weekly, measuring response approximately 24 hours after the previous dose. 2
• If 180 mg daily provides inadequate suppression, titrate upward: 240 mg each morning → 180 mg morning + 180 mg evening → 240 mg morning + 120 mg evening → 240 mg every 12 hours. 2
• The effective chronic dose range is 240–320 mg daily; in electrophysiologic studies, 320 mg daily significantly prolonged AV node conduction time, refractory period, and markedly narrowed the SVT induction zone. 3

Long-Term Efficacy

• Oral verapamil successfully prevented SVT recurrence in 14 of 15 patients (93%) followed for 3–31 months in prospective trials. 3
• Verapamil is more effective for AV nodal re-entrant tachycardia (AVNRT) than for SVT due to concealed accessory pathways. 3
• Both diltiazem and verapamil are well-tolerated pharmacologic alternatives to catheter ablation for ongoing SVT control. 1

Post-Conversion Strategy to Prevent Early Recurrence

• Administer 40 mg oral verapamil immediately after successful adenosine conversion to prevent early recurrence; this reduces recurrence rates significantly between 30–120 minutes and thereafter compared to adenosine alone. 5
• Monitor continuously for 6 hours in an acute care setting after conversion, as recurrence is most common in the first 2 hours. 5

Monitoring Requirements

• Monitor for bradyarrhythmias, hypotension, and signs of heart failure after initiating chronic verapamil therapy. 1
• Verapamil undergoes extensive hepatic metabolism; in patients with liver dysfunction, therapeutic plasma concentrations may be achieved with one-third the usual dose (elimination half-life prolonged to 14–16 hours). 2
• Approximately 90% of verapamil is protein-bound, and norverapamil (the active metabolite) reaches steady-state concentrations equal to verapamil itself with approximately 20% of the cardiovascular activity. 2

Common Pitfalls to Avoid

• Do not use verapamil as first-line acute therapy; the 2019 ESC guidelines downgraded verapamil/diltiazem in acute narrow-QRS tachycardia management, reserving them for third-line use after vagal maneuvers and adenosine. 6
• Never administer verapamil for wide-QRS tachycardia of unknown etiology, as this may precipitate ventricular fibrillation if the rhythm is ventricular tachycardia. 6
• Recognize that catheter ablation is now recommended as first-line therapy for recurrent symptomatic SVT, with single-procedure success rates of 94.3–98.5%; verapamil is appropriate only when ablation is declined or unsuitable. 1
• When switching from immediate-release to extended-release verapamil formulations, the total daily dose in milligrams remains the same. 2